BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28407442)

  • 1. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
    Malm M; Heinimäki S; Vesikari T; Blazevic V
    Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of three virus-derived nanoparticles as a vaccine against enteric pathogens; enterovirus, norovirus and rotavirus.
    Heinimäki S; Hankaniemi MM; Sioofy-Khojine AB; Laitinen OH; Hyöty H; Hytönen VP; Vesikari T; Blazevic V
    Vaccine; 2019 Dec; 37(51):7509-7518. PubMed ID: 31585726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.
    Blazevic V; Malm M; Arinobu D; Lappalainen S; Vesikari T
    Hum Vaccin Immunother; 2016 Mar; 12(3):740-8. PubMed ID: 26467630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo.
    Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    J Immunol Res; 2020; 2020():3194704. PubMed ID: 32411793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus Than Sequential Immunization.
    Malm M; Vesikari T; Blazevic V
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31684058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
    Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.
    Tamminen K; Lappalainen S; Huhti L; Vesikari T; Blazevic V
    PLoS One; 2013; 8(7):e70409. PubMed ID: 23922988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.
    Blazevic V; Lappalainen S; Nurminen K; Huhti L; Vesikari T
    Vaccine; 2011 Oct; 29(45):8126-33. PubMed ID: 21854823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.
    Lappalainen S; Pastor AR; Malm M; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
    Arch Virol; 2015 Aug; 160(8):2075-8. PubMed ID: 26016444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.
    Lappalainen S; Tamminen K; Vesikari T; Blazevic V
    Hum Vaccin Immunother; 2013 Sep; 9(9):1991-2001. PubMed ID: 23777748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.
    Badillo-Godinez O; Gutierrez-Xicotencatl L; Plett-Torres T; Pedroza-Saavedra A; Gonzalez-Jaimes A; Chihu-Amparan L; Maldonado-Gama M; Espino-Solis G; Bonifaz LC; Esquivel-Guadarrama F
    Vaccine; 2015 Aug; 33(35):4228-37. PubMed ID: 25850020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
    Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N
    Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of VP6 immunogenicity and protective efficacy against rotavirus by VP2 in a genetic immunization.
    Lopez-Guerrero DV; Arias N; Gutierrez-Xicotencatl L; Chihu-Amparan L; González A; Pedroza-Saavedra A; Rosas-Salgado G; Villegas-Garcia JC; Badillo-Godinez O; Fernandez G; Lopez S; Esquivel-Guadarrama F
    Vaccine; 2018 May; 36(22):3072-3078. PubMed ID: 28465094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internalization and antigen presentation by mouse dendritic cells of rotavirus VP6 preparations differing in nanostructure.
    Tamminen K; Heinimäki S; Gröhn S; Blazevic V
    Mol Immunol; 2020 Jul; 123():26-31. PubMed ID: 32388275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.
    Lappalainen S; Pastor AR; Tamminen K; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
    Hum Vaccin Immunother; 2014; 10(7):2039-47. PubMed ID: 25424814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
    Siadat-Pajouh M; Cai L
    Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA.
    McNeal MM; Stone SC; Basu M; Bean JA; Clements JD; Hendrickson BA; Choi AH; Ward RL
    Virology; 2006 Mar; 346(2):338-47. PubMed ID: 16375942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge.
    McNeal MM; Basu M; Bean JA; Clements JD; Lycke NY; Ramne A; Löwenadler B; Choi AH; Ward RL
    Vaccine; 2007 Aug; 25(33):6224-31. PubMed ID: 17629371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Mol Immunol; 2016 Oct; 78():27-37. PubMed ID: 27573255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine.
    Madore HP; Estes MK; Zarley CD; Hu B; Parsons S; Digravio D; Greiner S; Smith R; Jiang B; Corsaro B; Barniak V; Crawford S; Conner ME
    Vaccine; 1999 May; 17(19):2461-71. PubMed ID: 10392629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.